Examining the contribution of the FDA to the development of gene therapeutics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Epstein, S.L. Regulatory concerns in human gene therapy. Hum. Gene Ther. 2, 243–249 (1991).
Walters, L. Human gene therapy: Ethics and public policy. Hum. Gene Ther. 2, 115–122 (1991).
Wilson, C.A., Ng, T.-H. & Miller, A.E. Evaluation of recommendations for replication-competent retro-virus testing associated with use of retroviral vectors. Hum. Gene Ther. 8, 869–874 (1997).
Crystal, R.G. The gene as the drug. Nature Med. 1, 15–7 (1995).
Mamelok, R.D. in Clinical Pharmacology: Basic Principles in Therapeutics (eds. Melmon, K.L., Morrelli, H.F., Hoffman, B.B. & Nierenberg, D.W.) 911–921 (McGraw-Hill, Inc., New York, 1992).
Crystal, R.G. et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genet. 8, 42–51 (1994).
Wilson, J.M. Adenoviruses as gene-delivery vehicles. N. Engl. J. Med. 334, 1185–1187 (1996).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wagner, J., Burd, P. A new role for an old actor. Nat Med 3, 1084–1085 (1997). https://doi.org/10.1038/nm1097-1084
Issue Date:
DOI: https://doi.org/10.1038/nm1097-1084